A5078469285- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- Immunotherapy and Immune Responses
- Intramuscular injections and effects
- Viral Infections and Immunology Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- SARS-CoV-2 detection and testing
- Bacillus and Francisella bacterial research
- Parasites and Host Interactions
- Parasite Biology and Host Interactions
- Influenza Virus Research Studies
- Viral Infections and Vectors
- Trace Elements in Health
- Mosquito-borne diseases and control
- Dermatological and COVID-19 studies
- Long-Term Effects of COVID-19
- Bacterial Infections and Vaccines
- Vaccine Coverage and Hesitancy
- Malaria Research and Control
National Science and Technology Development Agency
2022-2025
National Center for Genetic Engineering and Biotechnology
2022-2025
Mahidol University
2016-2022
Siriraj Hospital
2022
The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve protection delta omicron variants.A total 224 individuals who completed 2-dose CoronaVac for 6 months were included. We studied reactogenicity immunogenicity after a with (BBIBP), viral vector...
The coronavirus 2019 omicron variant has surged rapidly and raises concerns about immune evasion even in individuals with complete vaccination, because it harbors mutations. Here we examine the capability of booster vaccination following CoronaVac/AZD1222 prime to induce neutralizing antibodies (NAbs) against (BA.1 BA.2) T-cell responses. A total 167 participants primed heterologous for 4-5 months were enrolled, receive AZD1222, BNT162b2, or mRNA-1273 as a third dose. Reactogenicity was...
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning immunity in vaccinated individuals is resulting increased numbers SARS-CoV-2 breakthrough infections. This study investigated binding antibody responses neutralizing activities against variants, patients with COVID-19 who had been fully CoronaVac (
The SARS-CoV-2 Omicron variant presents numerous mutations potentially able to evade neutralizing antibodies (NAbs) elicited by COVID-19 vaccines. Therefore, this study aimed provide evidence on a heterologous booster strategy overcome the waning immunity against variants.
This study examined the neutralizing activity and receptor-binding domain (RBD) antibody levels against wild-type omicron BA.1 BA.2 variants in individuals who received three doses of COVID-19 vaccination. The relationship between anti-RBD IgG live virus titers was examined. In total, 310 sera samples from after booster vaccination (third-dose) were tested for specific SARS-CoV-2 RBD surrogate neutralization test (sVNT). assay performed using foci-reduction (FRNT50). strongly correlated with...
Numerous studies have largely focused on short-term immunogenicity in recovered individuals post mRNA vaccination. However, understanding the long-term durability, particularly inactivated and adenoviral vectored vaccines, remains limited. We evaluated antibody responses, omicron variant neutralization, IFN-γ responses 119 previously infected vaccinated with CoronaVac or ChAdOx1 up to six months post-vaccination. Both vaccines elicited robust immune individuals, surpassing those who were...
Abstract Background The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve protection delta omicron variants. Methods A total 224 individuals who completed two-dose CoronaVac for six months were included. We studied reactogenicity immunogenicity following...
To assess the binding antibody response and strength of neutralization against Omicron BA.5 in serum samples from children with different antigen exposures (infection/vaccination) hybrid immunity.This study recruited aged 5-7 years. All were tested for anti-nucleocapsid immunoglobulin (Ig)G, anti-receptor domain (RBD) IgG, total anti-RBD Ig. Neutralizing antibodies (nAbs) determined using a focus reduction test.A 196 unvaccinated infection (n = 57), vaccination alone 71), immunity 68). Our...
Abstract This study examined the neutralizing activity and receptor binding domain (RBD) antibody levels against wild-type omicron BA.1 BA.2 variants in individuals who received three doses of COVID-19 vaccination. The relationship between SARS-CoV-2 RBD live virus titers was examined. In total, 310 sera samples from after booster vaccination (third dose) were tested for specific IgG surrogate neutralization test (sVNT). assay performed using foci-reduction (FRNT50). anti-RBD strongly...
Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning immunity in vaccinated individuals is resulting increased numbers SARS-CoV-2 breakthrough infections. This study investigated binding antibody responses neutralizing activities against patients with COVID-19 who had been fully CoronaVac ( n = 78), but not contracted 170), received AZD1222 as a third vaccination 210). Breakthrough infection was generally detected approximately 88...
There is a limited supply of COVID-19 vaccines, with less than 20% eligible populations in low-income countries having received one dose. Intradermal delivery fractional dose vaccines way to improve global vaccine access, but no studies have reported data on intradermal primary series vaccination. We conducted pilot study examine the safety and immunogenicity three regimens - heterologous regimen CoronaVac ChAdOx1 (CoronaVac-ChAdOx1), homologous (ChAdOx1-ChAdOx1), BNT162b2...
This cohort study, conducted between July and August 2023, evaluated the adverse events (AEs) immune response to a bivalent mRNA-1273.222 (containing sequences of original Wuhan-H1 strain Omicron BA.4/5 variant) booster vaccine in 122 participants. The study included individuals with diverse vaccination histories, their responses were assessed based on anti-receptor binding domain (RBD) IgG levels neutralizing antibodies against wild-type, BA.5, XBB.1.16 variants. Following administration...
Several countries have authorized a booster vaccine campaign to combat the spread of COVID-19. Data on persistence vaccine-induced immunity against new Omicron subvariants are still limited. Therefore, our study aimed determine serological immune response COVID-19 after CoronaVac-priming.
Abstract Background The coronavirus 2019 omicron variant has surged rapidly and raises concerns about immune evasion because it harbors mutations even in individuals with complete vaccination. Here, we examine the capability of booster vaccination to induce neutralizing antibodies (NAbs) against (BA.1 BA.2) T-cell responses. Methods A total 167 participants primed heterologous CoronaVac/AZD1222 were enrolled receive AZD1222, BNT162b2, or mRNA-1273 as a dose. Reactogenicity was recorded....
To compare the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine regimen one or two doses of inactivated followed by an in healthy children 5 11 years age, a prospective cohort study was performed at King Chulalongkorn Memorial Hospital Thailand March to June 2022. Healthy age were enrolled received (BNT162b2) (CoronaVac) BNT162b2 regimen. In addition, who BBIBP-CorV 1 3 months prior receive heterologous as third dose (booster). Reactogenicity assessed self-reported...
Humans infected with dengue virus (DENV) acquire long-term protection against the infecting serotype, whereas cross-protection other serotypes is short-lived. Long-term induced by low levels of type-specific neutralizing antibodies can be assessed using virus-neutralizing antibody test. However, this test laborious and time-consuming. In study, a blockade-of-binding enzyme-linked immunoassay was developed to assess activity set anti-E monoclonal blood samples from virus-infected or...
Abstract The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare problem worldwide since December 2019. third dose of heterologous vaccine was recently approved by World Health Organization. present study compared the reactogenicity and immunogenicity reduced standard booster BNT162b2 mRNA-1273 in adults who previously received two-dose CoronaVac vaccine. Results showed that headache, joint pain, diarrhea were more frequent 15 μg-than 30 μg-BNT162b2 groups, whereas...
Abstract Objectives The SARS-CoV-2 Omicron variant presents numerous mutations potentially able to evade neutralizing antibodies (NAbs) elicited by COVID-19 vaccines. Therefore, this study aimed provide evidence on a heterologous booster strategy overcome the waning immunity against variants. Methods Participants who completed Oxford/AstraZeneca (hereafter AZD1222) for 5-7 months were enrolled. reactogenicity and persistence of immunogenicity in both humoral cellular response after...
Abstract Objectives Several countries have authorized a booster vaccine campaign to combat the spread of COVID-19. Data on persistence vaccine-induced immunity against new Omicron subvariants are still limited. Therefore, our study aimed determine serological immune response COVID-19 after CoronaVac-priming. Methods A total 187 CoronaVac-primed participants were enrolled and received an inactivated (BBIBP), viral vector (AZD1222) or mRNA (full-/half-dose BNT162B2, full-/half-dose mRNA-1273)...
Abstract There is a limited supply of COVID-19 vaccines, with less than 20% eligible populations in low-income countries having received one dose. Intradermal delivery fractional dose vaccines way to improve global vaccine access, but no studies have reported data on intradermal primary series vaccination. We conducted pilot study examine the safety and immunogenicity three regimens – heterologous regimen CoronaVac ChAdOx1 (CoronaVac-ChAdOx1), homologous (ChAdOx1-ChAdOx1), BNT162b2...